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Reply
I appreciate the opportunity to respond to Dr Ouriel’s reflec-
tions regarding our article documenting the carotid endarterec-
tomy experience from the Division of Vascular Surgery, Mayo
Clinic, Rochester, Minn. The purpose of this study was to examine
the implications of high-risk criteria (as defined by the Food and
Drug Administration–approved, industry-sponsored SAPPHIRE
study) on outcomes following carotid endarterectomy (CEA). It is
our perception that these criteria are overly inclusive, that they
envelope a group of patients on whom we frequently operate, and
that the endarterectomy results from SAPPHIRE are inferior to
those achieved in our own practice (and likely in many other
centers of excellence). In our retrospective study in 776 consecu-
tive patients, we found no difference in the individual end points of
death, stroke, or myocardial infarction (MI) when comparing
high- and low-risk groups. The combined end point of death,
stroke, and MI did reach significance (P  .05) when comparing
high- and low-risk symptomatic patients, but not asymptomatic
patients. In addition, we identified only 4 factors predictive of
perioperative stroke: cervical radiation therapy, class III/IV an-
gina, age 60 years and, to a lesser degree, symptomatic presen-
tation. The high-risk patients in our series were, in fact, comparable
to those in SAPPHIRE, as defined in Tables I-III. Although these
tables faithfully reproduce the SAPPHIRE criteria, they are incor-
rectly referenced within the text; we appreciate Dr Ouriel’s bring-
ing this typographic error to our attention.
Dr Ouriel correctly points out that statistical analyses are
sometimes flawed or misinterpreted; to quote Mark Twain, “There
are lies, damn lies, and statistics.” Nevertheless, our practices,
especially as they relate to cerebrovascular disease—and particu-
larly in asymptomatic patients, where margins of efficacy are thin—
are typically guided by evidenced-based medicine and determined
by rigid analysis of peer-reviewed data, not by trends, perceptions,
or industry hype. These methods of exacting analysis have been
applied to the SAPPHIRE data set (which has not yet been
published or subject to peer review), demonstrating equivalency of
carotid angioplasty/stenting (CAS) to endarterectomy in high-risk
patients; these data will hopefully be used to achieve Food and
Drug Administration approval. As such, we stand by our conclu-
sions, as stated in the article, which are based on currently accepted
statistical analysis. In addition, while the composite end point of
stroke, death, and MI in our study was statistically different in
symptomatic patients, this difference was largely driven by the
occurrence of non-Q MI, much like SAPPHIRE. While “myocar-
dial enzyme leak” is clearly not a positive outcome, its significance
remains uncertain. Depending on the sensitivity of the biomarker
used, nearly 40% of patients having percutaneous coronary inter-
vention suffer this complication, and although these patients are at
increased risk of subsequent cardiac death, a cause-and-effect
relationship remains to be determined. Biomarker release follow-
ing coronary angioplasty, carotid endarterectomy, or CAS may
simply identify a group of patients already at risk for future coro-
nary events.1,2
With respect to Dr Ouriel’s final point, we could not be in
better agreement—vascular surgeons represent the group of phy-
sicians best able to manage patients with carotid artery disease. I
have personally been involved with carotid angiography and inter-
vention for nearly a decade, and remain active in clinical trials of
CAS. I have trained many of my vascular surgical colleagues and
have encouraged them to become proficient in these techniques so
that we, as a specialty, can remain at the forefront. It is imperative
that we take a leading role in carotid intervention, lest we become
a historical footnote.3 Perhaps, however, we see our respective
roles differently; I believe that it is my obligation to counsel
patients as to the risks, benefits, and long-term outcomes of all
available therapies (medical, interventional, and surgical) that re-
late to their particular disease, and to make a recommendation to
that specific individual on the basis of the available peer-reviewed
literature and the results of procedures performed within my own
institution.4 I will have neglected my duty by simply performing
the procedure “that the patient wants”—the one that “avoids a
neck incision” or is currently in vogue. While CAS may ultimately
become first-line therapy, carotid endarterectomy remains the
treatment of choice for the vast majority of patients with high-
grade carotid artery stenosis in our practice; further prospective,
randomized studies will hopefully further define the role of CAS in
both high-risk and low-risk patients.
Timothy M. Sullivan, MD
Mayo Clinic
Rochester, Minn
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